DK0565620T3 - Mitotoxin til behandling af karbeskadigelse - Google Patents
Mitotoxin til behandling af karbeskadigelseInfo
- Publication number
- DK0565620T3 DK0565620T3 DK92903777.8T DK92903777T DK0565620T3 DK 0565620 T3 DK0565620 T3 DK 0565620T3 DK 92903777 T DK92903777 T DK 92903777T DK 0565620 T3 DK0565620 T3 DK 0565620T3
- Authority
- DK
- Denmark
- Prior art keywords
- ligand
- treated
- cytotoxic agent
- conjugate
- vascular injury
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pretreatment Of Seeds And Plants (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63707491A | 1991-01-03 | 1991-01-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0565620T3 true DK0565620T3 (da) | 1996-01-22 |
Family
ID=24554442
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK92903777.8T DK0565620T3 (da) | 1991-01-03 | 1992-01-02 | Mitotoxin til behandling af karbeskadigelse |
Country Status (7)
Country | Link |
---|---|
US (1) | US5308622A (fr) |
EP (1) | EP0565620B1 (fr) |
AT (1) | ATE128034T1 (fr) |
AU (1) | AU1193492A (fr) |
DE (1) | DE69204990T2 (fr) |
DK (1) | DK0565620T3 (fr) |
WO (1) | WO1992011872A1 (fr) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5529932A (en) * | 1988-01-28 | 1996-06-25 | Pharmacia, S.P.A. | Isolated DNA encoding a plant ribosome inactivating protein from the leaves of saponaria officinalis |
US5635384A (en) * | 1990-06-11 | 1997-06-03 | Dowelanco | Ribosome-inactivating proteins, inactive precursor forms thereof, a process for making and a method of using |
US5478804A (en) * | 1990-09-19 | 1995-12-26 | The Salk Institute For Biological Studies | Treatment of tumorigenic pathophysiological conditions with FGF-cytoxic conjugates |
US6515009B1 (en) | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5811447A (en) * | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
GB9203533D0 (en) * | 1992-02-19 | 1992-04-08 | Erba Carlo Spa | Use of the conjugate between a fibroblast growth factor and a saporin in treating ocular pathologies |
US6749853B1 (en) * | 1992-03-05 | 2004-06-15 | Board Of Regents, The University Of Texas System | Combined methods and compositions for coagulation and tumor treatment |
US5965132A (en) | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
US5770609A (en) * | 1993-01-28 | 1998-06-23 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
US6306421B1 (en) | 1992-09-25 | 2001-10-23 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6251920B1 (en) | 1993-05-13 | 2001-06-26 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
US6395494B1 (en) * | 1993-05-13 | 2002-05-28 | Neorx Corporation | Method to determine TGF-β |
US6491938B2 (en) | 1993-05-13 | 2002-12-10 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
ES2355184T3 (es) | 1993-01-28 | 2011-03-23 | Boston Scientific Limited | Inhibidores terapéuticos de células de músculo liso vascular. |
US5595722A (en) * | 1993-01-28 | 1997-01-21 | Neorx Corporation | Method for identifying an agent which increases TGF-beta levels |
US6663881B2 (en) * | 1993-01-28 | 2003-12-16 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
WO1994026303A1 (fr) | 1993-05-13 | 1994-11-24 | Neorx Corporation | Prevention et traitement de pathologies associees a la proliferation anormale des cellules des muscles lisses |
US5599307A (en) * | 1993-07-26 | 1997-02-04 | Loyola University Of Chicago | Catheter and method for the prevention and/or treatment of stenotic processes of vessels and cavities |
US6551618B2 (en) | 1994-03-15 | 2003-04-22 | University Of Birmingham | Compositions and methods for delivery of agents for neuronal regeneration and survival |
US6037329A (en) * | 1994-03-15 | 2000-03-14 | Selective Genetics, Inc. | Compositions containing nucleic acids and ligands for therapeutic treatment |
US5824644A (en) * | 1994-07-07 | 1998-10-20 | G. D. Searle & Co. | Method of attenuating arterial stenosis |
AU3374795A (en) * | 1994-08-29 | 1996-03-22 | Prizm Pharmaceuticals, Inc. | Conjugates of vascular endothelial growth factor with targeted agents |
US5665591A (en) * | 1994-12-06 | 1997-09-09 | Trustees Of Boston University | Regulation of smooth muscle cell proliferation |
US5645839A (en) * | 1995-06-07 | 1997-07-08 | Trustees Of Boston University | Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis |
US7611533B2 (en) * | 1995-06-07 | 2009-11-03 | Cook Incorporated | Coated implantable medical device |
ATE377418T1 (de) | 1995-06-07 | 2007-11-15 | Poniard Pharmaceuticals Inc | Vorbeugung und behandlung von kardiovaskulären beschwerden mit tamoxifen-analogen |
JP2002515784A (ja) * | 1996-06-24 | 2002-05-28 | セレクティブ ジェネティクス,インコーポレイテッド | ヘパリン結合増殖因子結合体を含有するヘパリン処理医療用デバイス |
US20050043234A1 (en) * | 1996-10-16 | 2005-02-24 | Deisher Theresa A. | Novel FGF homologs |
US6342051B1 (en) * | 1997-06-12 | 2002-01-29 | Gholam A. Peyman | Treatment of anoxic tissue with angiogenesis-inducing implants |
AU9692198A (en) | 1997-10-10 | 1999-05-03 | Kevin J. Donahue | Gene delivery compositions and methods |
DE19853067A1 (de) * | 1998-11-17 | 2000-05-18 | Jomed Implantate Gmbh | Radioaktiver Stent |
US6695830B2 (en) | 1999-01-15 | 2004-02-24 | Scimed Life Systems, Inc. | Method for delivering medication into an arterial wall for prevention of restenosis |
US7470665B2 (en) | 1999-12-02 | 2008-12-30 | Zymogenetics, Inc. | Methods for targeting cells that express fibroblast growth receptor-3 or -2 |
US6827727B2 (en) | 2001-12-18 | 2004-12-07 | Radi Medical Systems Ab | Method and device for applying external pressure in combination with coagulant treatment of puncture wounds |
DE10222776A1 (de) * | 2002-05-15 | 2003-12-11 | Neumann Till | System zur wiederholten, aktiven Unterbrechung des Blutstroms |
AU2003279835B2 (en) * | 2002-10-07 | 2009-09-10 | Zymogenetics, Inc. | Methods of administering FGF18 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4956455A (en) * | 1984-03-05 | 1990-09-11 | The Salk Institute For Biological Studies | Bovine fibroblast growth factor |
DE3880766D1 (de) * | 1987-09-02 | 1993-06-09 | Ciba Geigy Ag | Konjugate von interferon alpha mit immunglobulinen. |
US5084556A (en) * | 1987-10-23 | 1992-01-28 | Genetics Institute, Inc. | Composition of M-CSF conjugated to cytotoxic agents and a method for treating cancers characterized by over-expression of the c-fms proto-oncogene |
US4950483A (en) * | 1988-06-30 | 1990-08-21 | Collagen Corporation | Collagen wound healing matrices and process for their production |
US5191067A (en) * | 1989-04-27 | 1993-03-02 | The Salk Institute For Biological Studies | Fibroblast growth factor conjugates |
-
1992
- 1992-01-02 WO PCT/US1992/000101 patent/WO1992011872A1/fr active IP Right Grant
- 1992-01-02 AU AU11934/92A patent/AU1193492A/en not_active Abandoned
- 1992-01-02 AT AT92903777T patent/ATE128034T1/de not_active IP Right Cessation
- 1992-01-02 DE DE69204990T patent/DE69204990T2/de not_active Expired - Fee Related
- 1992-01-02 EP EP92903777A patent/EP0565620B1/fr not_active Expired - Lifetime
- 1992-01-02 DK DK92903777.8T patent/DK0565620T3/da active
- 1992-07-16 US US07/915,056 patent/US5308622A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP0565620A1 (fr) | 1993-10-20 |
DE69204990T2 (de) | 1996-05-15 |
AU1193492A (en) | 1992-08-17 |
EP0565620B1 (fr) | 1995-09-20 |
DE69204990D1 (de) | 1995-10-26 |
ATE128034T1 (de) | 1995-10-15 |
US5308622A (en) | 1994-05-03 |
WO1992011872A1 (fr) | 1992-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0565620T3 (da) | Mitotoxin til behandling af karbeskadigelse | |
Creech Jr et al. | Experiences with isolation-perfusion technics in the treatment of cancer | |
Van Belle et al. | Accelerated endothelialization by local delivery of recombinant human vascular endothelial growth factor reduces in-stent intimal formation | |
DE60132343D1 (de) | Fgf-2 zur behandlung von erkrankungen der peripheralen arterien | |
JP2004523537A5 (fr) | ||
DE69920031T2 (de) | Verwendung von vegf-c und vegf-d genen oder proteinen zur vorbeugung der restenose | |
ATE209908T1 (de) | RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN | |
IL91796A0 (en) | Pharmaceutical preparations comprising gamma-interferon | |
WO2000021548A3 (fr) | Dose unitaire de fgf efficace du point de vue angiogenique et methode d'administration | |
JP2002527401A5 (fr) | ||
JP2016516071A (ja) | 瘢痕形成を軽減するためのsdf−1の使用 | |
WO2002058720A3 (fr) | Dose unitaire de fgf-2 efficace sur le plan angiogenique et methode d'utilisation | |
DE69921348D1 (de) | Fgf-2 angiogenische wirksame einheitdosis und ihrer verwendung | |
CA2089820C (fr) | Traitement d'etats physio-pathologiques tumorigenes a l'aide de produits de conjugaison cytotoxiques du facteur de croissance de fibroblastes | |
Koshima et al. | The free or pedicled saphenous flap | |
Furrer et al. | Lack of antitumour activity of human recombinant tumour necrosis factor-α, alone or in combination with melphalan in a nude mouse human melanoma xenograft system | |
Bond et al. | Use of ethoglucid in treatment of advanced malignant disease | |
Blakey et al. | What's new: Immunotoxins | |
Prescott | Doxil offers hope to KS sufferers | |
Murer | Engineered antibodies for the selective targeting of melanoma and colorectal cancer | |
Weiß et al. | The addition of human albumin to vinorelbine solution prevents venous irritation | |
Wennerstrand et al. | An Experimental Method for the Intraluminal Occlusion of Arterial Aneurysms | |
PTGA et al. | Synergistic effects of TNF-a and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study | |
Badgwell et al. | Intra-arterial administration of TNF-α followed by arterial ablation is an effective therapy for a regionally confined TNF-resistant rat mammary adenocarcinoma | |
Selye et al. | Choledochus ligature in the prevention of experimental thrombohemorrhagic duodenal necrosis |